TECHNOLOGY LICENSING OPPORTUNITY: Multidimensional Mass Fingerprinting for Antibiotic-Resistant Bacteria (MultiScan-AR)
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
TRIAD - DOE CONTRACTOR
Contract Value
Not provided
Codes & Classification
Solicitation Number
S-191477
NAICS
334516 - Analytical Laboratory Instrument Manufacturing
Classification Code
6630
Additional Details
Los Alamos National Laboratory (LANL), operating under the Department of Energy and managed by TRIAD as a DOE contractor, has issued a special notice regarding a technology licensing opportunity for its innovative Multidimensional Mass Fingerprinting for Antibiotic-Resistant Bacteria, known as MultiScan-AR. This technology is designed to transform routine mass spectrometry procedures into high-resolution diagnostic tools, enabling rapid identification of pathogens and their antibiotic-resistance profiles within minutes to hours—significantly faster than traditional methods that often require a full day.
The scope of this opportunity centers on licensing the MultiScan-AR technology, which leverages advanced multidimensional tandem mass spectrometry techniques. The process begins with the collection and lysis of microbial samples, followed by matrix-assisted laser desorption ionization mass spectrometry. Unlike conventional approaches that provide only basic strain differentiation, MultiScan-AR performs comprehensive scans across the entire mass range in both positive and negative ionization modes. This generates a dense dataset, capturing subtle molecular changes linked to antibiotic resistance. A dedicated data pipeline then organizes this information into a multidimensional mass fingerprint, facilitating precise organism identification and resistance profiling.
Key requirements and objectives for potential licensees include the integration of MultiScan-AR with existing mass spectrometry platforms—ranging from benchtop analyzers to portable field units—without the need for new hardware investments. The technology is particularly suited for hospital laboratories, point-of-care settings, field-forward environments, and biosurveillance operations. Its advantages include rapid turnaround times, the ability to distinguish closely related bacterial strains, reduced dependence on prior organism knowledge, and support for more accurate antibiotic prescriptions, thereby contributing to efforts to curb the spread of drug-resistant infections.
Expected deliverables for licensees involve the commercialization and deployment of MultiScan-AR within relevant market applications, such as clinical diagnostics, urgent care, public health monitoring, field medicine, analytical instrument platforms, and antimicrobial research. The technology is currently at Technology Readiness Level (TRL) 3 and is protected by a pending U.S. patent (LA-UR-26-27335).
The contracting entity is TRIAD, a federal office under the Department of Energy, with the place of performance located in Los Alamos, New Mexico. The opportunity is classified under NAICS Code 334516 (Analytical Laboratory Instrument Manufacturing) and Product Service Code 6630. There are no set-aside requirements for this notice.
Interested parties are encouraged to engage with LANL’s Technology Partnerships Office, which facilitates the licensing of patented and patent-pending inventions and copyrighted software through exclusive and non-exclusive agreements. This notice is not a solicitation for external development services, but rather an invitation to license and commercialize the technology. For further information or to initiate discussions, contact Caleb Ledgerwood or Lindsay Augustyn at [email protected]. Additional details and resources can be found at https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology and m.lanl.gov/tech-search.
The notice remains active, with a response deadline of October 1, 2026. Contractors and companies with expertise in analytical laboratory instrument manufacturing, diagnostics, or related fields are encouraged to evaluate this opportunity for alignment with their capabilities and strategic objectives.